RBC Capital Sticks to Its Hold Rating for Avid Bioservices (CDMO)

Written by Emily J. Thompson, Senior Investment Analyst

CDMO%

Source: Business Insider

Updated: Jan 09 2025

0mins

Source: Business Insider

Analyst Rating and Price Target: RBC Capital analyst Sean Dodge has maintained a Hold rating on Avid Bioservices with a price target of $12.50, while the stock closed at $12.38 recently.
Insider Activity and Sentiment: Corporate insider sentiment for Avid Bioservices is negative, with an increase in insiders selling shares, including a significant sale by the CEO, indicating potential concerns about the company's performance.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

RBC Capital Sticks to Its Hold Rating for Avid Bioservices (CDMO)

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Trump Denies Considering JPMorgan's Dimon for Fed Chair Position

General Motors Increases Dividend by 25% and Launches $6 Billion Buyback Program

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch